Exploring complement activation to develop biomarkers for systemic lupus erythematosus

Arthritis and Rheumatism

Volumn 50, Issue 11, 2004, Pages 3404-3407

  Tsokos, George C ^a,b  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; BIOLOGICAL MARKER; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4 BINDING PROTEIN; LECTIN; MANNOSE BINDING LECTIN; PROTEIN; PROTEIN C1; SERINE PROTEINASE; UNCLASSIFIED DRUG;

ANTIGEN ANTIBODY COMPLEX; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT HEMOLYSIS TEST; COMPLEMENT LECTIN PATHWAY; COMPLEX FORMATION; DIAGNOSTIC VALUE; EDITORIAL; GENE DUPLICATION; GENE STRUCTURE; GLOMERULONEPHRITIS; HUMAN; HYDROLYSIS; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR HISTOCOMPATIBILITY COMPLEX; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTIGENS, CD4; BIOLOGICAL MARKERS; CELL MEMBRANE; COMPLEMENT ACTIVATION; ERYTHROCYTES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RECEPTORS, COMPLEMENT;

EID: 8444233963     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.20602     Document Type: Editorial

References (18)

1. Boackle SA, Morris MA, Holers VM, Karp DR. Complement opsonization is required for presentation of immune complexes by resting peripheral blood B cells. J Immunol 1998;161:6537-43.
2. Manderson AP, Botto M, Walport MJ. The role of complement in the development of systemic lupus erythematosus. Annu Rev Immunol 2004;22:431-56.
3. Bohana-Kashtan O, Ziporen L, Donin N, Kraus S, Fishelson Z. Cell signals transduced by complement. Mol Immunol 2004;41:583-97.
4. Tsokos CG, Fleming SD. Autoimmunity, complement activation, tissue injury, and back. Curr Dir Autoimmun 2004;7:149-64.
5. Hajela K, Kojima M, Ambrus G, Wong KH, Moffatt BE, Ferluga J, et al. The biological functions of MBL-associated serine proteases (MASPs). Immunobiology 2002;205:467-75.
6. Holers VM, Thurman JM. The alternative pathway of complement in disease: opportunities for therapeutic targeting. Mol Immunol 2004;41:147-52.
7. Yang Y, Chung EK, Zhou B, Lhotta K, Hebert LA, Birmingham DJ, et al. The intricate role of complement component C4 in human systemic lupus erythematosus. Curr Dir Autoimmun 2004;7:98-132.
8. Pillemer SR, Austin HA III, Tsokos GC, Balow JE. Lupus nephritis: association between serology and renal biopsy measures. J Rheumatol 1988;15:284-8.
9. Moulds JM, Warner NB, Arnett FC. Complement component C4A and C4B levels in systemic lupus erythematosus: quantitation in relation to C4 null status and disease activity. J Rheumatol 1993;20:443-7.
10. Finco O, Li S, Cuccia M, Rosen FS, Carroll MC. Structural differences between the two human complement C4 isotypes affect the humoral immune response. J Exp Med 1992;175:537-43.
11. Ho A, Barr SG, Magder LS, Petri M. A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus. Arthritis Rheum 2001;44:2350-7.
12. Manzi S, Rairie JE, Carpenter AB, Kelly RH, Jagarlapudi SP, Sereika SM, et al. Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity. Arthritis Rheum 1996;39:1178-88.
13. Buyon JP, Tamerius J, Belmont HM, Abramson SB. Assessment of disease activity and impending flare in patients with systemic lupus erythematosus: comparison of the use of complement split products and conventional measurements of complement. Arthritis Rheum 1992;35:1028-37.
14. Manzi S, Navratil JS, Ruffing MJ, Liu CC, Danchenko N, Nilson SE, et al. Measurement of erythrocyte C4d and complement receptor 1 in systemic lupus erythematosus. Arthritis Rheum 2004;50:3596-604.
15. Wilson JF, Wong WW, Schur PH, Fearon DT. Mode of inheritance of decreased C3b receptors on erythrocytes of patients with systemic lupus erythematosus. N Engl J Med 1982;307:981-6.
16. Ross GD, Yount WJ, Walport MJ, Winfield JB, Parker CJ, Fuller CR, et al. Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation. J Immunol 1985;135:2005-14.
17. Aguado MT, Lambris JD, Tsokos GC, Burger RZ, Bitter-Suermann D, Tamerius JD, et al. Monoclonal antibodies against complement 3 neoantigens for detection of immune complexes and complement activation: relationship between immune complex levels, state of C3 and numbers of receptors for C3b. J Clin Invest 1985;76:1418-26.
18. Illei GG, Tackey E, Lapteva L, Lipsky PE. Biomarkers in systemic lupus erythematosus. I. General overview of biomarkers and their applicability. Arthritis Rheum 2004;50:1709-20.